Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLG | P00747 | 3/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | PLAT | P00750 | 1/20 | 0.61 |
| ▸ | NCF1 | P14598 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | KLKB1 | P03952 | 3/20 | 0.33 |
| ▸ | PLAU | P00749 | 2/20 | 0.33 |
| ▸ | THRA | P10827 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.33 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.33 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.33 |
| ▸ | ANPEP | P15144 | 1/20 | 0.32 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10067857 | 1.00 | PLG (0.61) | PLGLMNAPLATNCF1CYP2D6 | |
| SCHEMBL256670 | 0.83 | — | — | |
| SCHEMBL16850294 | 0.82 | PLG (0.61) | PLGLMNAPLATNCF1CYP2D6 | |
| SCHEMBL16887693 | 0.79 | PLG (0.37) | PLGLMNAPLATTHRATHRB | |
| SCHEMBL12267061 | 0.79 | PLG (0.64) | PLGLMNAPLATNCF1CYP2D6 | |
| SCHEMBL8275022 | 0.79 | PLG (0.64) | PLGLMNAPLATNCF1CYP2D6 | |
| Tranexamic Acid SCHEMBL21182345 | 0.78 | PLG (0.83) | PLGLMNAPLATNCF1CYP2D6 | |
| SCHEMBL15712882 | 0.77 | CYP2C9 (0.42) | PLGLMNAPLATCYP2D6THRA | |
| Tranexamic Acid SCHEMBL2184714 | 0.77 | PLG (0.91) | PLGLMNAPLATNCF1CYP2D6 | |
| SCHEMBL10489690 | 0.76 | PLG (0.67) | PLGLMNAPLATNCF1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180221501-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | NOVO NORDISK HEALTHCARE AG (CH) | 2018-08-09 | — | — | US | disclosed |
| US-20140329750-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | NOVO NORDISK HEALTHCARE AG (CH) | 2014-11-06 | — | — | US | disclosed |
| US-20140107324-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | NOVO NORDISK HEALTH CARE AG (CH) | 2014-04-17 | — | — | US | disclosed |
| US-20120172303-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | NOVO NORDISK HEALTH CARE AG (CH) | 2012-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329750-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | GHRHR, GHITM, SHBG | PLG 1197/4885LMNA 4446/4885PLAT 1709/4885 |
| US-20120172303-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | GHRHR, GHITM, SHBG | PLG 1197/4885LMNA 4446/4885PLAT 1709/4885 |
| US-20180221501-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | GHRHR, GHITM, SHBG | PLG 1197/4885LMNA 4446/4885PLAT 1709/4885 |
| US-20140107324-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | SHBG, GHRHR, GHITM | PLG 474/4885LMNA 2657/4885PLAT 1378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.